Exelixis Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Exelixis wird ein jährliches Gewinn- und Umsatzwachstum von 23.8% bzw. 8.4% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 24.1% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 16.2% betragen.

Wichtige Informationen

15.7%

Wachstumsrate der Gewinne

16.5%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	30.0%
Wachstumsrate der Einnahmen	6.5%
Zukünftige Eigenkapitalrendite	14.3%
Analystenabdeckung	Good
Zuletzt aktualisiert	21 Aug 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Exelixis Comes Up Aces

Aug 08

If EPS Growth Is Important To You, Exelixis (NASDAQ:EXEL) Presents An Opportunity

Jun 14

It's Unlikely That Exelixis, Inc.'s (NASDAQ:EXEL) CEO Will See A Huge Pay Rise This Year

May 24

Exelixis' (NASDAQ:EXEL) Strong Earnings Are Of Good Quality

May 07

Exelixis: With Patent Litigation Decision Due Soon, There Are Options

May 02

Exelixis, Inc.'s (NASDAQ:EXEL) Earnings Haven't Escaped The Attention Of Investors

Apr 22

Exelixis: Patent Woes And Challenging Market Dynamics Make For A Testy 2024

Mar 28

We Ran A Stock Scan For Earnings Growth And Exelixis (NASDAQ:EXEL) Passed With Ease

Feb 26

Exelixis: Bullish Despite The High Stakes Game Of Cabometyx Patent Battles

Jan 17

Exelixis, Inc.'s (NASDAQ:EXEL) Revenues Are Not Doing Enough For Some Investors

Dec 27

An Intrinsic Calculation For Exelixis, Inc. (NASDAQ:EXEL) Suggests It's 49% Undervalued

May 30

Exelixis initiated at outperform at JMP Securities on cash flow, Cabometyx franchise

Oct 18

Gewinn- und Umsatzwachstumsprognosen

NasdaqGS:EXEL - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	2,280	566	466	680	15
12/31/2025	2,074	447	437	568	20
12/31/2024	2,052	467	341	404	20
6/30/2024	2,014	350	166	316	N/A
3/31/2024	1,847	205	185	318	N/A
12/31/2023	1,830	208	170	333	N/A
9/30/2023	1,774	92	134	396	N/A
6/30/2023	1,714	164	213	389	N/A
3/31/2023	1,664	154	118	299	N/A
12/31/2022	1,611	182	224	363	N/A
9/30/2022	1,638	308	343	385	N/A
6/30/2022	1,555	273	310	359	N/A
3/31/2022	1,521	298	453	509	N/A
12/31/2021	1,435	231	337	401	N/A
9/30/2021	1,254	164	275	338	N/A
6/30/2021	1,157	94	218	272	N/A
3/31/2021	1,031	65	152	192	N/A
12/31/2020	988	112	179	209	N/A
9/30/2020	958	152	310	334	N/A
6/30/2020	998	282	372	391	N/A
3/31/2020	979	294	408	421	N/A
12/31/2019	968	321	514	527	N/A
9/30/2019	956	612	465	474	N/A
6/30/2019	910	642	541	563	N/A
3/31/2019	856	650	473	506	N/A
12/31/2018	854	690	382	416	N/A
9/30/2018	745	368	316	364	N/A
6/30/2018	672	323	203	237	N/A
3/31/2018	585	253	N/A	169	N/A
12/31/2017	452	154	N/A	166	N/A
9/30/2017	410	150	N/A	197	N/A
6/30/2017	320	58	N/A	154	N/A
3/31/2017	257	6	N/A	122	N/A
12/31/2016	191	-70	N/A	210	N/A
9/30/2016	124	-147	N/A	90	N/A
6/30/2016	71	-181	N/A	61	N/A
3/31/2016	43	-186	N/A	60	N/A
12/31/2015	37	-162	N/A	-141	N/A
9/30/2015	35	-178	N/A	-156	N/A
6/30/2015	31	-195	N/A	-180	N/A
3/31/2015	30	-229	N/A	-208	N/A
12/31/2014	25	-261	N/A	-235	N/A
9/30/2014	22	-281	N/A	-233	N/A
6/30/2014	21	-286	N/A	-232	N/A
3/31/2014	27	-275	N/A	-216	N/A
12/31/2013	31	-245	N/A	-199	N/A
9/30/2013	35	-226	N/A	-190	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: EXELDas prognostizierte Gewinnwachstum (23.8% pro Jahr) liegt über der Sparquote (2.4%).

Ertrag vs. Markt: EXELDie Erträge des Unternehmens (23.8% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (14.8% pro Jahr).

Hohe Wachstumserträge: EXELDie Erträge des Unternehmens werden voraussichtlich steigen, jedoch nicht deutlich.

Einnahmen vs. Markt: EXELDie Einnahmen des Unternehmens (6.8% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (8.5% pro Jahr).

Hohe Wachstumseinnahmen: EXELDie Einnahmen des Unternehmens (8.4% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: EXELDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (16.2%).

Exelixis Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus EPS estimates increase by 37%

Exelixis, Inc. Reaffirms Earnings Guidance for the Year 2024

Exelixis, Inc. Provides Earnings Guidance for the for Fiscal Year 2024

Consensus EPS estimates fall by 10%

Consensus EPS estimates increase by 11%

Exelixis, Inc. Provides Earnings Guidance for the Fiscal Year 2023

Recent updates

Independent Director recently sold US$907k worth of stock

Consensus EPS estimates increase by 37%

Insider notifies of intention to sell stock

Exelixis Comes Up Aces

Exelixis, Inc. Announces Initiation of Phase 1 Clinical Trial Evaluating XB010 in Patients with Advanced Solid Tumors

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Exelixis, Inc. (NasdaqGS:EXEL) announces an Equity Buyback for $500 million worth of its shares.

Exelixis, Inc. Announces U.S. Food and Drug Administration Accepted the Supplemental New Drug Application for Cabozantinib for Patients with Advanced Neuroendocrine Tumors

Exelixis, Inc. to Report Q2, 2024 Results on Aug 06, 2024

If EPS Growth Is Important To You, Exelixis (NASDAQ:EXEL) Presents An Opportunity

Independent Director recently sold US$576k worth of stock

It's Unlikely That Exelixis, Inc.'s (NASDAQ:EXEL) CEO Will See A Huge Pay Rise This Year

Independent Director notifies of intention to sell stock

Exelixis Announces Settlement of CABOMETYX® (cabozantinib) Patent Litigation with Cipla Limited and Cipla USA

Exelixis' (NASDAQ:EXEL) Strong Earnings Are Of Good Quality

Exelixis: With Patent Litigation Decision Due Soon, There Are Options

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Exelixis, Inc. Reaffirms Earnings Guidance for the Year 2024

Exelixis, Inc.'s (NASDAQ:EXEL) Earnings Haven't Escaped The Attention Of Investors

Exelixis, Inc., Annual General Meeting, May 30, 2024

Exelixis, Inc. to Report Q1, 2024 Results on Apr 30, 2024

Exelixis: Patent Woes And Challenging Market Dynamics Make For A Testy 2024

Independent Director notifies of intention to sell stock

Executive Vice President of Commercial recently sold US$1.0m worth of stock

We Ran A Stock Scan For Earnings Growth And Exelixis (NASDAQ:EXEL) Passed With Ease

Executive Vice President of Commercial notifies of intention to sell stock

Full year 2023 earnings: EPS exceeds analyst expectations

Exelixis, Inc. Provides Earnings Guidance for the for Fiscal Year 2024

Exelixis, Inc. Announces Detailed Results of Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer Presented at ASCO GU 2024

Bristol Myers Squibb and Exelixis, Inc. Announce Four-Year Follow-Up Results from the CheckMate -9ER Trial Evaluating Opdivo (cabozantinib)

Exelixis: Bullish Despite The High Stakes Game Of Cabometyx Patent Battles

Exelixis, Inc. (NasdaqGS:EXEL) announces an Equity Buyback for $450 million worth of its shares.

Exelixis, Inc. (NasdaqGS:EXEL) announces an Equity Buyback for $450 million worth of its shares.

Exelixis, Inc.'s (NASDAQ:EXEL) Revenues Are Not Doing Enough For Some Investors

Executive VP notifies of intention to sell stock

Executive VP notifies of intention to sell stock

Exelixis Announces Initiation of the Stellar-305 Phase 2/3 Pivotal Trial Evaluating Zanzalintinib in Combination with Pembrolizumab in Patients with Previously Untreated Recurrent or Metastatic Head and Neck Cancer

Exelixis, Inc. Announces Encouraging Results from Expansion Cohort of Phase 1b STELLAR-001 Trial Evaluating Zanzalintinib in Patients with Advanced Kidney Cancer at IKCS 2023

Third quarter 2023 earnings released: EPS: US$0.003 (vs US$0.23 in 3Q 2022)

Consensus EPS estimates fall by 10%

Exelixis, Inc. Announces Detailed Results from Phase 3 Cabinet Pivotal Trial Evaluating Cabozantinib in Advanced Neuroendocrine Tumors Presented at ESMO 2023

Exelixis, Inc. to Report Q3, 2023 Results on Nov 01, 2023

CEO, President & Director exercised options and sold US$2.1m worth of stock

Exelixis, Inc. Announces Positive Results from Phase 3 CABINET Pivotal Trial Evaluating Cabozantinib in Advanced Pancreatic and Extra-Pancreatic Neuroendocrine Tumors

Exelixis, Inc. Announces Vicki L. Goodman Concludes Her Service as Executive Vice President, Product Development & Medical Affairs, and Chief Medical Officer

New major risk - Revenue and earnings growth

Executive Vice President of Commercial recently sold US$632k worth of stock

Consensus EPS estimates increase by 11%

Exelixis, Inc. Provides Earnings Guidance for the Fiscal Year 2023

Executive VP notifies of intention to sell stock

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Exelixis, Inc. to Report Q2, 2023 Results on Aug 01, 2023

Exelixis, Inc. Elects Dave Johnson to its Board of Directors

An Intrinsic Calculation For Exelixis, Inc. (NASDAQ:EXEL) Suggests It's 49% Undervalued

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Exelixis, Inc. Provides Earnings Guidance for the Fiscal Year 2023

Exelixis Announces Departure of Lance Willsey, M.D. From Board of Directors

Executive VP notifies of intention to sell stock

Independent Director notifies of intention to sell stock

Executive VP notifies of intention to sell stock

Insider notifies of intention to sell stock

Independent Director notifies of intention to sell stock

Bristol-Myers Squibb Company and Exelixis, Inc. Announces Opdivo in Combination with Cabometyx Shows Durable Survival with over Three Years of Follow-Up in the Checkmate -9Er Trial in First-Line Advanced Renal Cell Carcinoma

Exelixis, Inc. and Sairopa B.V. Announces US FDA Clears Investigational New Drug Application for ADU-1805 in Patients with Advanced Solid Tumors

Consensus EPS estimates fall by 15%

Executive Vice President of Commercial notifies of intention to sell stock

Full year 2022 earnings: EPS exceeds analyst expectations

Exelixis, Inc. Provides Revenue Guidance for Fiscal Year 2023

CEO, President & Director exercised options and sold US$816k worth of stock